Interventional, Randomized, Double-blind, Active-controlled Study of the Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 12 May 2019
Price : $35 *
At a glance
- Drugs LU AF-35700 (Primary) ; Olanzapine; Risperidone
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms Anew
- Sponsors Lundbeck A/S
- 26 Feb 2019 This trial has been completed in Bulgaria, according to European Clinical Trials Database.
- 08 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.